Latest market price
49.85
+0.48+0.97%
AXGNQT67AxoGen, Inc.·NASDAQ
49.85+0.97%
News
Up 1.0% — Axogen: Taking The Friction Out Of Nerve Repair (seekingalpha.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index—P/E—EPS (ttm)-0.65Insider Own6.61%Shs Outstand59.73MPerf Week31.12%
Market Cap2.98BForward P/E70.67EPS next Y0.71Insider Trans-3.46%Shs Float54.51MPerf Month33.32%
Enterprise Value2.65BPEG—EPS next Q0.14Short Float9.40%Perf Quarter8.46%
Income-33.00MP/S11.15EPS this Y79.50%Short Ratio4.19Perf Half Y16.94%
Sales267.00MP/B6.00EPS next Y27.26%ROA-5.80%Short Interest5.12MPerf YTD52.31%
Book/sh8.30P/C8.56EPS next 5Y33.68%ROE-11.34%52W High52.91 -5.78%Perf Year119.80%
Cash/sh5.83P/FCF175.15EPS past 3/5Y—ROIC-2.68%52W Low21.68 129.94%Perf 3Y1254.62%
Dividend Est.—EV/EBITDA—Sales past 3/5Y17.41% 14.97%Gross Margin74.18%Volatility6.86% 4.43%Perf 5Y255.82%
Dividend TTM—EV/Sales9.92EPS Y/Y TTM—Oper. Margin-5.17%ATR (14)2.32Perf 10Y456.98%
Dividend Ex-DateJan 27, 2010Quick Ratio10.67Sales Y/Y TTM24.19%Profit Margin-11.96%RSI (14)74.62Recom2.14
Dividend Gr. 3/5Y— 75.54%Current Ratio12.02EPS Q/Q75.00%SMA2027.90%Beta1.15Target Price58.13
Payout0.00%Debt/Eq0.04Sales Q/Q26.67%SMA5016.35%Rel Volume1.32Prev Close49.37
Employees622LT Debt/Eq0.04EarningsFeb 23SMA20025.68%Avg Volume1.40MPrice49.85
IPO DateDec 17, 1986Option/ShortYes / YesEPS/Sales Surpr.59.90% 3.24%Net Debt/EBITDA—Volume1,842,470Change0.97%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-29-26ReiteratedLake StreetBuy$55 → $58
Oct-29-26ReiteratedRaymond JamesOutperform$53 → $57
Oct-29-26ReiteratedLeerink PartnersOutperform$56
Oct-29-26ReiteratedHC Wainwright & Co.Buy$53 → $56
Oct-29-26ReiteratedBarclaysOverweight$50 → $60
Oct-28-26ReiteratedJefferiesBuy$55 → $60
Oct-28-26ReiteratedMizuho Securities$40 → $65
Oct-23-26ReiteratedBarclaysOverweight$55 → $50
Oct-06-26InitiatedBarclaysOverweight$55
Oct-01-26ReiteratedTruist SecuritiesBuy$60 → $53
Latest News· Times ET
Nov-02-26
Oct-30-26
Oct-30-2612:25PM
Oct-29-26
Oct-28-26
Oct-28-2606:06PM
Oct-23-26
Oct-21-26
Oct-16-26
Oct-14-26
Oct-12-26
Oct-05-26
Oct-03-26
Oct-01-26
Company

AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue267225187159—————
Cost of Goods Sold Incl. D&A68584537—————
Gross Profit198167142122—————
Selling, General and Administrative Excl. Other175142117116—————
Research and Development38332827—————
Other Operating Expense
-1000—————
Operating Income-14-8-3-21—————
Interest Expense3883—————
Unusual Expense
—————————
Non-Operating Income (Expense)-16023—————
Net Income Before Taxes-33-16-10-22—————
Income Taxes
0000—————
Consolidated Net Income-33-16-10-22—————
Net Income From Continuing Operations-33-16-10-22—————
Net Income-33-16-10-22—————
EPS (Recurring)-0.65-0.34-0.23-0.51—————
EPS (Basic, Before Extraordinaries)-0.65-0.34-0.23-0.51—————
EPS (Diluted)-0.65-0.34-0.23-0.51—————
EBITDA-2106-13—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio10.276.693.881.85—————
Gross Margin74.1674.2275.9476.73—————
Operating Margin-5.24-3.56-1.60-13.21—————
Net Margin-12.36-7.11-5.35-13.84—————
Shares Outstanding55464443—————
Market Capitalization2,7421,506725294—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$57.27$45.27$33.26$21.25$9.25● Close Price0.00M2.64M5.29M7.93M10.58MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
TYNDALL JOSEPH A.DirectorSep 02 '26Sale49.703,500173,94010,650Sep 04
Wendell Amy McBrideDirectorAug 11 '26Option Exercise14.8513,353198,292121,329Aug 12
Wendell Amy McBrideDirectorAug 11 '26Sale48.4213,353646,592107,976Aug 12
Began Marc AEVP & General CounselAug 10 '26Sale47.3467,5003,195,78850,135Aug 12
Began Marc AEVP & General CounselAug 10 '26Option Exercise8.1667,500550,800117,635Aug 12
Weiler Kathy JohnsonDirectorAug 07 '26Sale45.3014,150640,9670Aug 11
Burke William P. Mr.DirectorJun 19 '26Option Exercise0.0028,300014,250Jun 23
THOMAS PAULDirectorJun 19 '26Option Exercise0.0037,734032,395Jun 23
Levine Alan MDirectorJun 19 '26Option Exercise0.0028,300050,893Jun 23
Weiler Kathy JohnsonDirectorJun 19 '26Option Exercise0.0028,300014,150Jun 23
Wendell Amy McBrideDirectorJun 19 '26Option Exercise0.0028,3000107,976Jun 23
TYNDALL JOSEPH A.DirectorJun 19 '26Option Exercise0.0028,300014,150Jun 23
JOHNSON JOHNDirectorJun 19 '26Option Exercise0.0028,300014,150Jun 23
Wendell Amy McBrideDirectorMay 08 '26Option Exercise14.851,64724,45895,473May 12
Wendell Amy McBrideDirectorMay 08 '26Sale42.601,64770,16293,826May 12
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.